Learn About Gastroenteropancreatic Neuroendocrine Tumor

What is the definition of Gastroenteropancreatic Neuroendocrine Tumor?
Gastroenteropancreatic neuroendocrine tumor (GEP-NET), also known as carcinoid tumor or islet cell tumor, is a rare disease of cells that control hormones and nerves. Gastroenteropancreatic neuroendocrine tumors most frequently occur in the esophagus, pancreas, stomach, small intestine, colon, rectum, or appendix and can be benign or cancerous. Malignant (cancerous) gastroenteropancreatic neuroendocrine tumors can spread to other parts of the body, such as the lymph nodes, lungs, liver, and bones.
Save information for later
Sign Up
What are the symptoms of Gastroenteropancreatic Neuroendocrine Tumor?
Some individuals with gastroenteropancreatic neuroendocrine tumor may not experience any symptoms. Symptoms of gastroenteropancreatic neuroendocrine tumor may include unexplained weight loss; loss of appetite; nausea; yellowing of the skin, whites of eyes, and mucous membranes (jaundice); facial flushing; and severe diarrhea or gastrointestinal bleeding.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Gastroenteropancreatic Neuroendocrine Tumor?
Treatment for a gastroenteropancreatic neuroendocrine tumor that is fast-growing or has spread usually involves surgery to remove the tumor and medications to slow tumor growth, such as octreotide, lanreotide, and telotristat; targeted therapies, such as everolimus and sunitinib; chemotherapy; and peptide receptor radiotherapy (Lu 177 or Lutathera). In individuals with a slow-growing gastroenteropancreatic neuroendocrine tumor, a wait and watch strategy may be followed before deciding on surgery.
Who are the top Gastroenteropancreatic Neuroendocrine Tumor Local Doctors?
Elite
Highly rated in
12
conditions
Oncology

Boston Medical Center

Boston, MA 

Matthew Kulke is an Oncologist in Boston, Massachusetts. Dr. Kulke has been practicing medicine for over 30 years and is rated as an Elite doctor by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor. He is also highly rated in 12 other conditions, according to our data. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Carcinoid Syndrome, and Gastroenteropancreatic Neuroendocrine Tumor. He is board certified in Medical Oncology and licensed to treat patients in Massachusetts. Dr. Kulke is currently accepting new patients.

Elite
Highly rated in
14
conditions
Hematology Oncology
Oncology

Moffitt Cancer Center

Tampa, FL 

Jonathan Strosberg is a Hematologist Oncology specialist and an Oncologist in Tampa, Florida. Dr. Strosberg has been practicing medicine for over 23 years and is rated as an Elite doctor by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor. He is also highly rated in 14 other conditions, according to our data. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Gastroenteropancreatic Neuroendocrine Tumor, and Familial Pancreatic Cancer. He is board certified in Hematology/oncology and licensed to treat patients in Florida. Dr. Strosberg is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn more
Elite
Highly rated in
8
conditions
Oncology
Hematology Oncology

UK Albert B Chandler Hospital

Lexington, KY 

Lowell Anthony is an Oncologist and a Hematologist Oncology doctor in Lexington, Kentucky. Dr. Anthony has been practicing medicine for over 43 years and is rated as an Elite doctor by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor. He is also highly rated in 8 other conditions, according to our data. His top areas of expertise are Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor, Carcinoid Syndrome, and Diarrhea. He is board certified in Medical Oncology and licensed to treat patients in Louisiana and Kentucky. Dr. Anthony is currently accepting new patients.

What are the latest Gastroenteropancreatic Neuroendocrine Tumor Clinical Trials?
Imaging With 68Ga-DOTA-peptides and Peptide Receptor Radionuclide Therapy With 177Lu-DOTA-peptides of Gastroenteropancreatic Neuroendocrine Tumors: Interest of Intra-arterial Hepatic Infusion in Patients With Dominant Liver Metastases
Match to trials
Find the right clinical trials for you in under a minute
Get started
A Post Marketing Surveillance on Lutathera® (Lutetium (177Lu) Oxodotreotide, 177Lu-DOTA0-Tyr3-Octreotate) in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) in Korea
What are the Latest Advances for Gastroenteropancreatic Neuroendocrine Tumor?
177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience.
Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.
Tired of the same old research?
Check Latest Advances
Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors.